FDA greenlights Abbott's blood glucose test strips

Kaitlyn Dmyterko | | Health Imaging | Screening
The FDA has granted Abbott Diabetes Care 510(k) clearance for its FreeStyle Lite blood glucose test strips, which minimize interference by using a GDH-FAD enzyme that is unaffected by non-glucose sugars.

The Alameda, Calif.-based company said that standard test strips utilize the GDH-PQQ enzyme, which has the potential to be affected by non-glucose sugars maltose or galactose and could interfere with testing. According to Abbott, the test trips are compatible with FreeStyle Lite blood glucose monitoring systems.

Abbott said that the FreeStyle Lite test strips will ship to customers in July and will be widely available in August.

Kaitlyn Dmyterko

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.